ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN RISPERIDONE KOMBINASI DAN HALOPERIDOL KOMBINASI PADA PASIEN SKIZOFRENIA DI RSJ. DR. V. L. RATUMBUYSANG PROVINSI SULAWESI UTARA
Abstract
Skizofrenia adalah gangguan jiwa berat dan kronis yang signifikan dihubungkan dengan masalah kesehatan jangka panjang, sosial dan beban keuangan. Penelitian ini bertujuan untuk melakukan analisis efektivitas biaya penggunaan risperidone kombinasi dan haloperidol kombinasi pada pasien skizofrenia di RSJ. Prof. DR. V. L. Ratumbuysang Provinsi Sulawesi Utara pada bulan April-Juli 2018. Data dikumpulkan secara retrospektif dan prospektif. Efektifitas pengobatan diukur menggunakan instrumen Positive and Negative Scala Score (PANSS). Hasil penelitian menunjukkan bahwa rerata biaya total kelompok risperidone kombinasi maupun haloperidol kombinasi secara statistik tidak menunjukkan perbedaan yang signifikan (p=1,35). Outcome kilinik kelompok risperidone kombinasi berdasarkan persen penurunan PANSS signifikan lebih baik dibandingkan kelompok haloperidol kombinasi dengan nilai p = 0,002. Berdasarkan perolehan Rasio Efektifitas Biaya (REB) risperidone kombinasi menjadi pilihan yang dominan dibandingkan kelompok haloperidol kombinasi.
References
Crismon MN, Argo TR, and Buckley PF. Scizophrenia. in Dipiro JT, Talbert RL, Yee GC, Well BG, and Posey LM, Pharmacotherapy : A Pathopysiologic Approach. 7th ed. McGraw Hill, Washington DC. 1099-1122. 2008.
Garcia-Ruiz AJ, Pérez-Costillas L, Montesinos CA, Alcalde Javier, Itziar O, Casado AM, Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses, Health Economic Review, 2012;2:8.
Ayano Gatinet, Schizophrenia: A Concise Overview of Ethiology, Epidemiology Diagnosis and Management: Review of literatures. Journal of Schizophrenia Research 2016;3:1026.
Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS). Kementrian Kesehatan Republik Indonesia. Jakarta. 2013.
Miyamoto S, Ducan GE, Marx CE, and Lieberman JA, Treatments for Schizophrenia : a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry. 2005;10:79-104.
MB. Jayaram, P. Hosalili. Risperidone versus Haloperidol for Schizophrenia. Cochane Library. 2005.
Geddes J, Freemantle N, Harisson P, Bebbington P, Atypical antypsychotics in the treatment of schizophrenia : systemic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
Leucht S. Pitschel-Wals G. Abraham D. Kissling W. Efficacy and extrapyramidal side – effect of the new antipsychotics olanzapine, quetiapine, Risperidone, and sentridole compared to conventional antipsychotics and placebo. A meta-analysis of randomozed controlled trialis. Schizophrenia Research. 1999;35:51-68.
Davis JM, Chen N, Glick ID, A meta-analysis of the efficacy of second – generation antipsychotics. Arch Gen Paychiatry. 2003;60:553-564.
Dipiro T Joseph, Talbert L Robert et al, Pharmacotherapy A pathophysiologic Approach. Sixth Edition. 2008.
Aberg JA, Lacy CF, Amstrong LL, Goldman MP, and Lance LL, Drug information handbook. 17th edition. Lexi-Comp for the American Pharmacists Association. 2009.
Leucht Stevan, Heres Stephan, K. Warner and Davis M. Jhon, Evidence-based pharmacotherapy of schizophrenia. International Journal of Neuropsychopharmacology. 2011;14:269-284.
Andayani TM, Farmakoekonomi prinsip dan metodelogi. I. Bursa Ilmu. Yogyakarta. 2013.
Sugiyono, Metode Penelitian Manajemen Pendekatan : Kuantitatif, Kualitatif, Kombinasi (Mixed Method), Penelitian Tindakan (Action Researsch). Penelitian Evaluasi. Bandung: Penerbit Alfabeta. 2013.
Green JF, A Comparison f he edative and amnesic ffect of Chlorpromazine and Lorazepam. Psychopharmacology (Berl.). 1996;128(1):67-73.
Leucht Stevan, Kane MJ, Kissling Werner, Hamman Johannes, Estchel Eva, Engel R. Rofli. What does the PANSS? Schizophrenia Research. 2005;70:231-238.
Pedoman Definisi PANSS. Bagian Pasikiatri Fakultas Kedokteran Universitas Indonesia. Jakarta. 1994.
Departemen Kesehatan Republik Indonesia, Bina Pelayanan Kefarmasian. Pedoman Penerapan Kajian Farmakoekonomi. Kemenetrian Kesehatan Republik Indonesia. Jakarta. 2013.
Sadock BJ, Sadock VA. Schizophrenia. In: Kaplan & Sadock’s synopsis of psychiatry, behavioural sciences/clinical psychiatry. 9th edition (pp 471-504). Philadelphia : Lippincott Williams & Wilkins; 2003.
Fujimaki Koichiro, Takahashi Terumichi, Morinobu Shigeru, Association of Typical versus Atypival antipsycotics with symptoms and quality of life in schizophrenia. 2012.
Stahl SM, Primary care companion. J clin Psychiatry. 2003:5:9-13.
Honneycutt AA et al, Guide to Analyzing the Cost-Effectiveness of Community Public Health Prevention Approaches (pp. 56-57), USA: Research Triangle Park, 2006.
Downloads
Published
Issue
Section
License
The copyright to this article is transferred to Universitas Hasanuddin (UNHAS) if and when the article is accepted for publication. The undersigned hereby transfers all rights in and to the paper including without limitation all copyrights to UNHAS. The undersigned hereby represents and warrants that the paper is original and that he/she is the author of the paper, except for material that is clearly identified as to its original source, with permission notices from the copyright owners where required. The undersigned represents that he/she has the power and authority to make and execute this assignment.
We declare that:
- This paper has not been published in the same form elsewhere.
- It will not be submitted anywhere else for publication prior to acceptance/rejection by this Journal.
- A copyright permission is obtained for materials published elsewhere and which require this permission for reproduction.
Furthermore, I/We hereby transfer the unlimited rights of publication of the above-mentioned paper in whole to UNHAS The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline, online) or any other reproductions of similar nature.
The corresponding author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. This agreement is to be signed by at least one of the authors who have obtained the assent of the co-author(s) where applicable. After submission of this agreement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted.
